Publicaciones en colaboración con investigadores/as de University of Ulm (25)

2024

  1. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 9, pp. 2132-2141

  2. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

    HemaSphere

2023

  1. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2022

  1. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

    Drugs and Aging, Vol. 39, Núm. 11, pp. 863-874

  2. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

    The oncologist, Vol. 27, Núm. 7, pp. e561-e570

  3. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

    npj Breast Cancer, Vol. 7, Núm. 1

  2. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

    Blood

  3. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials (European Journal of Clinical Pharmacology, (2021), 77, 1, (1-12), 10.1007/s00228-020-02951-8)

    European Journal of Clinical Pharmacology

  4. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

    European Journal of Clinical Pharmacology, Vol. 77, Núm. 1

  5. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

2019

  1. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

    Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 13, Núm. 4, pp. 2723-2725

  2. Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

    European Journal of Cancer, Vol. 118, pp. 169-177

  3. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45

  4. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential

    Cardiovascular Diabetology, Vol. 18, Núm. 1

2018

  1. Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.

    Annals of Oncology

2017

  1. Association analysis identifies 65 new breast cancer risk loci

    Nature, Vol. 551, Núm. 7678, pp. 92-94

  2. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712

  3. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

    Nature Genetics, Vol. 49, Núm. 12, pp. 1767-1778